Modeling Pathogenesis of Huntington’s Disease with Inducible Neuroprogenitor Cells

被引:0
作者
G. Dong
J. M. Ferguson
A. J. Duling
R. G. Nicholas
D. Zhang
K. Rezvani
S. Fang
M. J. Monteiro
S. Li
X-J. Li
H. Wang
机构
[1] University of South Dakota,Division of Basic Biomedical Sciences, Sanford School of Medicine
[2] University of South Dakota,Department of Biology
[3] University of Maryland,Center for Biomedical Engineering and Technology
[4] Emory University School of Medicine,Department of Human Genetics
来源
Cellular and Molecular Neurobiology | 2011年 / 31卷
关键词
Huntington’s disease; Pathogenesis; Huntingtin; Polyglutamine; Neuron; Neuroprogenitor;
D O I
暂无
中图分类号
学科分类号
摘要
Huntington’s disease (HD) is caused by an abnormal expansion of CAG trinucleotide repeats encoding polyglutamine (polyQ) in the first exon of the huntingtin (htt) gene. Despite considerable efforts, the pathogenesis of HD remains largely unclear due to a paucity of models that can reliably reproduce the pathological characteristics of HD. Here, we report a neuronal cell model of HD using the previously established tetracycline regulated rat neuroprogenitor cell line, HC2S2. Stable expression of enhanced green fluorescence protein tagged htt exon 1 (referred to as 28Q and 74Q, respectively) in the HC2S2 cells did not affect rapid neuronal differentiation. However, compared to the cells expressing wild type htt, the cell line expressing mutant htt showed an increase in time-dependent cell death and neuritic degeneration, and displayed increased vulnerability to oxidative stress. Increased protein aggregation during the process of neuronal aging or when the cells were exposed to oxidative stress reagents was detected in the cell line expressing 74Q but not in its counterpart. These results suggest that the neuroprogenitor cell lines mimic the major neuropathological characteristics of HD and may provide a useful tool for studying the neuropathogenesis of HD and for high throughput screening of therapeutic compounds.
引用
收藏
页码:737 / 747
页数:10
相关论文
共 50 条
  • [41] Huntington's disease
    MacDonald, ME
    Gines, S
    Gusella, JF
    Wheeler, VC
    NEUROMOLECULAR MEDICINE, 2003, 4 (1-2) : 7 - 20
  • [42] SUMO-modifying Huntington's disease
    Soares, Ericks S.
    Prediger, Rui D.
    Brocardo, Patricia S.
    Cimarosti, Helena, I
    IBRO NEUROSCIENCE REPORTS, 2022, 12 : 203 - 209
  • [43] Huntingtin processing in pathogenesis of Huntington disease
    Qin, ZH
    Gu, ZL
    ACTA PHARMACOLOGICA SINICA, 2004, 25 (10) : 1243 - 1249
  • [44] Huntingtin processing in pathogenesis of Huntington disease
    Zheng-hong QIN
    Laboratory of Cellular Neurobiology
    ActaPharmacologicaSinica, 2004, (10) : 3 - 9
  • [45] The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease
    Chih-Wei Tung
    Pin-Yu Huang
    Siew Chin Chan
    Pei-Hsun Cheng
    Shang-Hsun Yang
    Journal of Biomedical Science, 28
  • [46] Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis
    Gipson, Theresa A.
    Neueder, Andreas
    Wexler, Nancy S.
    Bates, Gillian P.
    Housman, David
    RNA BIOLOGY, 2013, 10 (11) : 1647 - 1652
  • [47] The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease
    Tung, Chih-Wei
    Huang, Pin-Yu
    Chan, Siew Chin
    Cheng, Pei-Hsun
    Yang, Shang-Hsun
    JOURNAL OF BIOMEDICAL SCIENCE, 2021, 28 (01)
  • [48] Gut Bacteria Regulate the Pathogenesis of Huntington's Disease in Drosophila Model
    Chongtham, Anjalika
    Yoo, Jung Hyun
    Chin, Theodore M.
    Akingbesote, Ngozi D.
    Huda, Ainul
    Marsh, J. Lawrence
    Khoshnan, Ali
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [49] Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis
    Chuang, Chia-Lung
    Demontis, Fabio
    AGEING RESEARCH REVIEWS, 2021, 69
  • [50] Huntington's Disease Update
    Suessmuth, S. D.
    Saft, C.
    Reilmann, R.
    Orth, M.
    Landwehrmeyer, G. B.
    AKTUELLE NEUROLOGIE, 2013, 40 (07) : 377 - 392